{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:05:50Z","timestamp":1792004750503,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["NIHR302495"],"award-info":[{"award-number":["NIHR302495"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Magnetic resonance imaging (MRI) biomarkers are vital for multiple sclerosis (MS) clinical research and trials but quantifying them requires multi-contrast protocols and limits the use of abundant single-contrast hospital archives. We developed MindGlide, a deep learning model to extract brain region and white matter lesion volumes from any single MRI contrast. We trained MindGlide on 4247 brain MRI scans from 2934 MS patients across 592 scanners, and externally validated it using 14,952 scans from 1,001 patients in two clinical trials (primary-progressive MS and secondary-progressive MS trials) and a routine-care MS dataset. The model outperformed two state-of-the-art models when tested against expert-labelled lesion volumes. In clinical trials, MindGlide detected treatment effects on T2-lesion accrual and cortical and deep grey matter volume loss. In routine-care data, T2-lesion volume increased with moderate-efficacy treatment but remained stable with high-efficacy treatment. MindGlide uniquely enables quantitative analysis of archival single-contrast MRIs, unlocking insights from untapped hospital datasets.<\/jats:p>","DOI":"10.1038\/s41467-025-58274-8","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T05:07:44Z","timestamp":1744002464000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Enabling new insights from old scans by repurposing clinical MRI archives for multiple sclerosis research"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4970-2340","authenticated-orcid":false,"given":"Philipp","family":"Goebl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jed","family":"Wingrove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abdelmannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0476-7220","authenticated-orcid":false,"given":"Barbara","family":"Brito Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Stutters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Da Graca","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owain","family":"Kenway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Rossor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2446-1106","authenticated-orcid":false,"given":"Evangeline","family":"Wassmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4266-0106","authenticated-orcid":false,"given":"Douglas L.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8432-7021","authenticated-orcid":false,"given":"D. Louis","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Hemingway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6283-150X","authenticated-orcid":false,"given":"Sridar","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Chataway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3076-2682","authenticated-orcid":false,"given":"Declan","family":"Chard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Eugenio","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3543-3706","authenticated-orcid":false,"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff J. M.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0203-3909","authenticated-orcid":false,"given":"Neil P.","family":"Oxtoby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Hacohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4333-8496","authenticated-orcid":false,"given":"Alan","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2439-350X","authenticated-orcid":false,"given":"Daniel C.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7485-1367","authenticated-orcid":false,"given":"Olga","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6652-3512","authenticated-orcid":false,"given":"Arman","family":"Eshaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"58274_CR1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2216399120","volume":"120","author":"B Billot","year":"2023","unstructured":"Billot, B. et al. Robust machine learning segmentation for large-scale analysis of heterogeneous clinical brain MRI datasets. Proc. Natl. Acad. Sci. 120, e2216399120 (2023).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"58274_CR2","doi-asserted-by":"publisher","first-page":"eadd3607","DOI":"10.1126\/sciadv.add3607","volume":"9","author":"JE Iglesias","year":"2023","unstructured":"Iglesias, J. E. et al. SynthSR: A public AI tool to turn heterogeneous clinical brain scans into high-resolution T1-weighted images for 3D morphometry. Sci. Adv. 9, eadd3607 (2023).","journal-title":"Sci. Adv."},{"key":"58274_CR3","doi-asserted-by":"publisher","first-page":"102789","DOI":"10.1016\/j.media.2023.102789","volume":"86","author":"B Billot","year":"2023","unstructured":"Billot, B. et al. SynthSeg: Segmentation of brain MRI scans of any contrast and resolution without retraining. Med. Image Anal. 86, 102789 (2023).","journal-title":"Med. Image Anal."},{"key":"58274_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2020.117471","volume":"225","author":"S Cerri","year":"2021","unstructured":"Cerri, S. et al. A contrast-adaptive method for simultaneous whole-brain and lesion segmentation in multiple sclerosis. NeuroImage 225, 117471 (2021).","journal-title":"NeuroImage"},{"key":"58274_CR5","doi-asserted-by":"publisher","unstructured":"Cardoso, M. J. et al. MONAI: An open-source framework for deep learning in healthcare. https:\/\/doi.org\/10.48550\/ARXIV.2211.02701 (2022)","DOI":"10.48550\/ARXIV.2211.02701"},{"key":"58274_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41592-020-01008-z","volume":"18","author":"F Isensee","year":"2021","unstructured":"Isensee, F., Jaeger, P. F., Kohl, S. A. A., Petersen, J. & Maier-Hein, K. H. nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. Nat. Methods 18, 203\u2013211 (2021).","journal-title":"Nat. Methods"},{"key":"58274_CR7","doi-asserted-by":"publisher","unstructured":"Laso, P. et al. Quantifying white matter hyperintensity and brain volumes in heterogeneous clinical and low-field portable MRI. https:\/\/doi.org\/10.48550\/ARXIV.2312.05119 (2023).","DOI":"10.48550\/ARXIV.2312.05119"},{"key":"58274_CR8","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1136\/jnnp-2022-329333","volume":"93","author":"R Zivadinov","year":"2022","unstructured":"Zivadinov, R. et al. Thalamic atrophy measured by artificial intelligence in a multicentre clinical routine real-world study is associated with disability progression. J. Neurol. Neurosurg. Psychiatry 93, 1128\u20131136 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"58274_CR9","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41746-023-00940-6","volume":"6","author":"M Barnett","year":"2023","unstructured":"Barnett, M. et al. A real-world clinical validation for AI-based MRI monitoring in multiple sclerosis. Npj Digit. Med. 6, 196 (2023).","journal-title":"Npj Digit. Med."},{"key":"58274_CR10","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi, P. A. et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 13, 657\u2013665 (2014).","journal-title":"Lancet Neurol."},{"key":"58274_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","volume":"17","author":"R Kapoor","year":"2018","unstructured":"Kapoor, R. et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 17, 405\u2013415 (2018).","journal-title":"Lancet Neurol."},{"key":"58274_CR12","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00415-014-7264-4","volume":"261","author":"TL Vollmer","year":"2014","unstructured":"Vollmer, T. L. et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J. Neurol. 261, 773\u2013783 (2014).","journal-title":"J. Neurol."},{"key":"58274_CR13","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold, R. et al. Placebo-Controlled Phase 3 Study of Oral BG\u221212 for Relapsing Multiple Sclerosis. N. Engl. J. Med. 367, 1098\u20131107 (2012).","journal-title":"N. Engl. J. Med."},{"key":"58274_CR14","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox, R. J. et al. Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis. N. Engl. J. Med. 367, 1087\u20131097 (2012).","journal-title":"N. Engl. J. Med."},{"key":"58274_CR15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1177\/13524585211037909","volume":"28","author":"R Gold","year":"2022","unstructured":"Gold, R. et al. Long-term safety and efficacy of dimethyl fumarate for up to 13\u2009years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results. Mult. Scler. Houndmills Basingstoke Engl. 28, 801\u2013816 (2022).","journal-title":"Mult. Scler. Houndmills Basingstoke Engl."},{"key":"58274_CR16","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos, L. et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 391, 1263\u20131273 (2018).","journal-title":"Lancet"},{"key":"58274_CR17","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","volume":"387","author":"F Lublin","year":"2016","unstructured":"Lublin, F. et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 387, 1075\u20131084 (2016).","journal-title":"Lancet"},{"key":"58274_CR18","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S1474-4422(20)30347-1","volume":"19","author":"BAC Cree","year":"2020","unstructured":"Cree, B. A. C. et al. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 19, 988\u2013997 (2020).","journal-title":"Lancet Neurol."},{"key":"58274_CR19","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton, C. et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult. Scler. J. 26, 1816\u20131821 (2020).","journal-title":"Mult. Scler. J."},{"key":"58274_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban, X. et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N. Engl. J. Med. 376, 209\u2013220 (2017).","journal-title":"N. Engl. J. Med."},{"key":"58274_CR21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant, A. et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 90, 777\u2013788 (2018).","journal-title":"Neurology"},{"key":"58274_CR22","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jamaneurol.2022.1025","volume":"79","author":"A Cagol","year":"2022","unstructured":"Cagol, A. et al. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis. JAMA Neurol. 79, 682 (2022).","journal-title":"JAMA Neurol."},{"key":"58274_CR23","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos, L. et al. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol. 77, 1132 (2020).","journal-title":"JAMA Neurol."},{"key":"58274_CR24","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/S0140-6736(13)62242-4","volume":"383","author":"J Chataway","year":"2014","unstructured":"Chataway, J. et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet Lond. Engl. 383, 2213\u20132221 (2014).","journal-title":"Lancet Lond. Engl."},{"key":"58274_CR25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ejrad.2009.09.029","volume":"74","author":"M Becker","year":"2010","unstructured":"Becker, M. et al. Imaging of the optic nerve. Eur. J. Radiol. 74, 299\u2013313 (2010).","journal-title":"Eur. J. Radiol."},{"key":"58274_CR26","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.neuroimage.2007.10.026","volume":"39","author":"RG Boyes","year":"2008","unstructured":"Boyes, R. G. et al. Intensity non-uniformity correction using N3 on 3-T scanners with multichannel phased array coils. NeuroImage 39, 1752\u20131762 (2008).","journal-title":"NeuroImage"},{"key":"58274_CR27","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.nicl.2014.01.004","volume":"4","author":"V Popescu","year":"2014","unstructured":"Popescu, V. et al. Accurate GM atrophy quantification in MS using lesion-filling with co-registered 2D lesion masks. Neuroimage Clin. 4, 366\u2013373 (2014).","journal-title":"Neuroimage Clin."},{"key":"58274_CR28","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1109\/TPAMI.2012.143","volume":"35","author":"H Wang","year":"2013","unstructured":"Wang, H. et al. Multi-Atlas Segmentation with Joint Label Fusion. IEEE Trans. Pattern Anal. Mach. Intell. 35, 611\u2013623 (2013).","journal-title":"IEEE Trans. Pattern Anal. Mach. Intell."},{"key":"58274_CR29","doi-asserted-by":"publisher","first-page":"11050","DOI":"10.1073\/pnas.200033797","volume":"97","author":"B Fischl","year":"2000","unstructured":"Fischl, B. & Dale, A. M. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc. Natl Acad. Sci. USA 97, 11050\u201311055 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"58274_CR30","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.neuroimage.2005.02.018","volume":"26","author":"J Ashburner","year":"2005","unstructured":"Ashburner, J. & Friston, K. J. Unified segmentation. Neuroimage 26, 839\u2013851 (2005).","journal-title":"Neuroimage"},{"key":"58274_CR31","doi-asserted-by":"publisher","first-page":"64323","DOI":"10.1109\/ACCESS.2019.2917620","volume":"7","author":"Z Gong","year":"2019","unstructured":"Gong, Z., Zhong, P. & Hu, W. Diversity in Machine Learning. IEEE Access 7, 64323\u201364350 (2019).","journal-title":"IEEE Access"},{"key":"58274_CR32","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S1474-4422(12)70003-0","volume":"11","author":"M Filippi","year":"2012","unstructured":"Filippi, M. et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol. 11, 349\u2013360 (2012).","journal-title":"Lancet Neurol."},{"key":"58274_CR33","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S1474-4422(15)00393-2","volume":"15","author":"M Filippi","year":"2016","unstructured":"Filippi, M. et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 15, 292\u2013303 (2016).","journal-title":"Lancet Neurol."},{"key":"58274_CR34","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41586-022-04554-y","volume":"604","author":"RAI Bethlehem","year":"2022","unstructured":"Bethlehem, R. A. I. et al. Brain charts for the human lifespan. Nature 604, 525\u2013533 (2022).","journal-title":"Nature"},{"key":"58274_CR35","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1212\/WNL.0000000000000433","volume":"82","author":"JF Sumowski","year":"2014","unstructured":"Sumowski, J. F. et al. Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS. Neurology 82, 1776\u20131783 (2014).","journal-title":"Neurology"},{"key":"58274_CR36","doi-asserted-by":"publisher","unstructured":"Ulyanov, D., Vedaldi, A. & Lempitsky, V. Instance Normalization: The Missing Ingredient for Fast Stylization. https:\/\/doi.org\/10.48550\/ARXIV.1607.08022 (2016).","DOI":"10.48550\/ARXIV.1607.08022"},{"key":"58274_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.neuroimage.2016.12.064","volume":"148","author":"A Carass","year":"2017","unstructured":"Carass, A. et al. Longitudinal multiple sclerosis lesion segmentation: Resource and challenge. NeuroImage 148, 77\u2013102 (2017).","journal-title":"NeuroImage"},{"key":"58274_CR38","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.dib.2017.04.004","volume":"12","author":"A Carass","year":"2017","unstructured":"Carass, A. et al. Longitudinal multiple sclerosis lesion segmentation data resource. Data Brief 12, 346\u2013350 (2017).","journal-title":"Data Brief"},{"key":"58274_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12021-017-9348-7","volume":"16","author":"\u017d Lesjak","year":"2018","unstructured":"Lesjak, \u017d. et al. A Novel Public MR Image Dataset of Multiple Sclerosis Patients With Lesion Segmentations Based on Multi-rater Consensus. Neuroinformatics 16, 51\u201363 (2018).","journal-title":"Neuroinformatics"},{"key":"58274_CR40","doi-asserted-by":"crossref","unstructured":"Ronneberger, O., Fischer, P. & Brox, T. U-Net: convolutional networks for biomedical image segmentation. In Medical Image Computing and Computer-Assisted Intervention \u2013 MICCAI 2015 (eds Navab, N., Hornegger, J., Wells, W. & Frangi, A.) 234\u2013241 (Springer, 2015).","DOI":"10.1007\/978-3-319-24574-4_28"},{"key":"58274_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30695-9","volume":"13","author":"M Antonelli","year":"2022","unstructured":"Antonelli, M. et al. The Medical Segmentation Decathlon. Nat. Commun. 13, 4128 (2022).","journal-title":"Nat. Commun."},{"key":"58274_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-20314-w","volume":"12","author":"A Eshaghi","year":"2021","unstructured":"Eshaghi, A. et al. Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. Nat. Commun. 12, 1\u201312 (2021).","journal-title":"Nat. Commun."},{"key":"58274_CR43","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1109\/TMI.2015.2418298","volume":"34","author":"MJ Cardoso","year":"2015","unstructured":"Cardoso, M. J. et al. Geodesic information flows: spatially-variant graphs and their application to segmentation and fusion. IEEE Trans. Med. Imaging 34, 1976\u20131988 (2015).","journal-title":"IEEE Trans. Med. Imaging"},{"key":"58274_CR44","doi-asserted-by":"publisher","unstructured":"Colato, E. et al. Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes. J. Neurol. Neurosurg. Psychiatry, jnnp-2020-325610 https:\/\/doi.org\/10.1136\/jnnp-2020-325610 (2021).","DOI":"10.1136\/jnnp-2020-325610"},{"key":"58274_CR45","doi-asserted-by":"publisher","unstructured":"MONAI Consortium. MONAI: Medical Open Network for AI. Zenodo, https:\/\/doi.org\/10.5281\/ZENODO.4323058 (2022).","DOI":"10.5281\/ZENODO.4323058"},{"key":"58274_CR46","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1006\/nimg.1998.0395","volume":"9","author":"AM Dale","year":"1999","unstructured":"Dale, A. M., Fischl, B. & Sereno, M. I. Cortical Surface-Based Analysis: I. Segmentation and Surface Reconstruction. NeuroImage 9, 179\u2013194 (1999).","journal-title":"NeuroImage"},{"key":"58274_CR47","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.neuroimage.2006.01.021","volume":"31","author":"RS Desikan","year":"2006","unstructured":"Desikan, R. S. et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. NeuroImage 31, 968\u2013980 (2006).","journal-title":"NeuroImage"},{"key":"58274_CR48","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1006\/nimg.2002.1040","volume":"17","author":"SM Smith","year":"2002","unstructured":"Smith, S. M. et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. NeuroImage 17, 479\u2013489 (2002).","journal-title":"NeuroImage"},{"key":"58274_CR49","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","volume":"15","author":"N Scolding","year":"2015","unstructured":"Scolding, N. et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract. Neurol. 15, 273\u2013279 (2015).","journal-title":"Pract. Neurol."},{"key":"58274_CR50","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2217\/cer-2020-0267","volume":"10","author":"IA Samjoo","year":"2021","unstructured":"Samjoo, I. A. et al. Efficacy classification of modern therapies in multiple sclerosis. J. Comp. Eff. Res. 10, 495\u2013507 (2021).","journal-title":"J. Comp. Eff. Res."},{"key":"58274_CR51","doi-asserted-by":"crossref","unstructured":"Goebl, P. et al. Repurposing Clinical MRI Archives for Multiple Sclerosis Research with a Flexible, Single-Contrast Approach: New Insights from Old Scans. www.github.com\/MS-PINPOINT\/mindGlide (2025).","DOI":"10.1101\/2024.03.29.24305083"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58274-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58274-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58274-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T05:07:58Z","timestamp":1744002478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58274-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["58274"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-58274-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"3 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.C. is a consultant for Hoffmann-La Roche. In the last three years he has been a consultant for Biogen, has received research funding from Hoffmann-La Roche, the International Progressive MS Alliance, the MS Society, the Medical Research Council, and the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre, and a speaker\u2019s honorarium from Novartis. He co-supervises a clinical fellowship at the National Hospital for Neurology and Neurosurgery, London, which is supported by Merck. F.B. acts as a member of the steering committee or Data Safety Monitoring Board for Biogen, Merck, ATRI\/ACTC and Prothena. Consultant for Roche, Celltrion, Rewind Therapeutics, Merck, IXICO, Jansen, Combinostics. Research agreements with Merck, Biogen, GE Healthcare, Roche. Co-founder and shareholder of Queen Square Analytics LTD. O.C. is a NIHR Research Professor (RP-2017-08-ST2-004); over the last 2 years, member of independent DSMB for Novartis; she gave a teaching talk in a Merck local symposium, and contributed to an Advisory Board for Biogen; she is Deputy Editor of Neurology, for which she receives an honorarium; she has received research grant support from the MS Society of Great Britain and Northern Ireland, the NIHR UCLH Biomedical Research Centre, the Rosetree Trust, the National MS Society, and the NIHR-HTA. C.H. reports grant support from the MRC and MS Society. She has served as a consultant to Novartis, Roche, UCB and Sanofi. S.N. has received research funding from the Canadian Institutes of Health Research, the International Progressive MS Alliance, the Myelin Repair Foundation, Immunotec, and F. Hoffman LaRoche, not related to the current work; he is a consultant for Sana Biotech, has received a speaker\u2019s honorarium from Novartis Canada, and is a part-time employee of NeuroRx Research. In the last 3 years, J.C. has received support from the Health Technology Assessment (HTA) Programme (National Institute for Health Research, NIHR), the UK MS Society, the US National MS Society and the Rosetrees Trust. He is supported in part by the NIHR University College London Hospitals (UCLH) Biomedical Research Centre, London, UK. He has been a local principal investigator for a trial in MS funded by MS Canada. A local principal investigator for commercial trials funded by: Ionis and Roche; and has taken part in advisory boards\/consultancy for Biogen, Contineum Therapeutics, InnoCare, Lucid, Merck, NervGen, Novartis and Roche. G.J.M.P. is a shareholder and director of, and receives salary from, Bioxydyn Limited. He is a shareholder and director of Queen Square Analytics Limited. He is a shareholder and director of Quantitative Imaging Limited. D.C.A. is a shareholder and director of Queen Square Analytics Limited. In the past three years, A.E. has received research grants from the Medical Research Council (MRC), NHS England, Imperial College Healthcare Trust, National Institute for Health and Social Care Research (NIHR), Innovate UK, Biogen, Merck, and Roche. He has served as an advisory board member of Merck Serono and Bristol Myers Squib. He is the founder and equity stakeholder in Queen Square Analytics Limited. He serves on the editorial board of Neurology (American Academy of Neurology). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3149"}}